Vimarsana
Biggest News Aggregation in the World

Page 7 - Jane Lowe News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jane Lowe. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jane Lowe Today - Breaking & Trending Today

23 Life Sciences Trends to Watch for in 2023 - Vimarsana News

23 Life Sciences Trends to Watch for in 2023

Published: January 5, 2023

23 Life Sciences Trends to Watch for in 2023

Source: biospectrumasia.com
Related Topics:
United StatesUnited KingdomArunachal PradeshYin ChangSouth AustraliaJawa TimurNational University Of SingaporeSingapore GeneralSouth KoreaIndustrial Technology Research InstituteKao HsiungJeff WeiselZuellig PharmaJin KohJane LoweSamsung BiologicsDaiichi SankyoRaman SinghBio FarmaGoh Khoon SengAlex ZhavoronkovYogesh RaiArvind VaishnavCureapp DtxAgency For Science
KAZIA LAUNCHES PRECLINICAL COLLABORATION WITH QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE AND ANNOUNCES PATENT FILING - Vimarsana News

KAZIA LAUNCHES PRECLINICAL COLLABORATION WITH QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE AND ANNOUNCES PATENT FILING

Published: December 15, 2022

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce a collaboration with...

Source: prnewswire.com
Related Topics:
New South WalesJane LoweSudha RaoBerghofer Medical Research InstituteIr DepartmentKazia Therapeutics LimitedBristol Myers SquibbKazia TherapeuticsMedical Research InstituteProfessor Sudha RaoProfessor RaoPrincipal InvestigatorMore InformationPlease ContactTherapeutics LimitedOrphan Drug DesignationFast Track DesignationRare Pediatric Disease DesignationOrphan Designation
COMPELLING PRECLINICAL DATA FOR KAZIA'S EVT801 PUBLISHED IN PEER-REVIEWED CANCER RESEARCH JOURNAL - Vimarsana News

COMPELLING PRECLINICAL DATA FOR KAZIA'S EVT801 PUBLISHED IN PEER-REVIEWED CANCER RESEARCH JOURNAL

Published: December 1, 2022

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the publication of...

Source: prnewswire.com
Related Topics:
United StatesNew South WalesJames GarnerJean Pierre DelordJane LowePrnewswire Kazia Therapeutics LimitedClaudius Regaud InstituteUniversity Cancer Institute Of ToulouseCancer CenterAmerican Association Of Cancer ResearchToulouse University HospitalCancer Research CommunicationsIr DepartmentKazia Therapeutics LimitedBristol Myers SquibbKazia TherapeuticsTherapeutics LimitedMichael PaillasseUniversity Cancer InstituteAmerican AssociationCancer ResearchProfessor Jean Pierre DelordChief Executive OfficerMore InformationPlease Contact
KAZIA'S PAXALISIB DEMONSTRATES POSITIVE MONOTHERAPY EFFICACY SIGNALS IN PRECLINICAL MODELS OF MELANOMA - Vimarsana News

KAZIA'S PAXALISIB DEMONSTRATES POSITIVE MONOTHERAPY EFFICACY SIGNALS IN PRECLINICAL MODELS OF MELANOMA

Published: October 27, 2022

SYDNEY, Oct. 27, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is please...

Source: businessinsider.com
Related Topics:
United StatesSalt Lake CityNew South WalesUniversity Of UtahUnited KingdomCity OfJane LoweSheri HolmenGennie ParkmanPrnewswire Kazia Therapeutics LimitedHuntsman Cancer InstituteIr DepartmentKazia Therapeutics LimitedInternational CongressSociety For Melanoma ResearchKazia TherapeuticsTherapeutics LimitedProfessor Sheri HolmenMelanoma ResearchProfessor HolmenChief Executive OfficerMore InformationPlease ContactOrphan Drug DesignationFast Track Designation
PNOC CLINICAL STUDY OF KAZIA'S PAXALISIB IN CHILDHOOD BRAIN CANCER EXPANDS INTERNATIONALLY - Vimarsana News

PNOC CLINICAL STUDY OF KAZIA'S PAXALISIB IN CHILDHOOD BRAIN CANCER EXPANDS INTERNATIONALLY

Published: October 6, 2022

SYDNEY, Oct. 6, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today anno...

Source: businessinsider.com
Related Topics:
United StatesNew South WalesSan FranciscoJames GarnerJane LoweUniversity Of CaliforniaPrnewswire Kazia Therapeutics LimitedChimerix IncHunter Medical Research InstituteOncology ConsortiumIr DepartmentKazia Therapeutics LimitedUniversity Of NewcastleKazia TherapeuticsMcdonald Jones FoundationInternational Symposium On Pediatric NeuroTherapeutics LimitedPacific Pediatric Neuro Oncology ConsortiumChief Executive OfficerAssociate Professor Matt DunChad Tough DefeatMcdonald JonesInternational SymposiumPediatric Neuro OncologyProfessor Dun